| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy | 14 | 2021 | 91 | 4.990 |
Why?
|
| Killer Cells, Natural | 11 | 2019 | 86 | 3.790 |
Why?
|
| CD8-Positive T-Lymphocytes | 10 | 2021 | 150 | 3.090 |
Why?
|
| Neoplasms | 16 | 2020 | 1033 | 2.830 |
Why?
|
| Antineoplastic Agents | 13 | 2021 | 756 | 2.800 |
Why?
|
| Lung Neoplasms | 10 | 2023 | 336 | 2.760 |
Why?
|
| Lymphocytes | 4 | 2023 | 116 | 2.610 |
Why?
|
| Cell Communication | 9 | 2023 | 93 | 2.310 |
Why?
|
| T-Lymphocytes | 12 | 2019 | 341 | 2.260 |
Why?
|
| Immunotherapy, Adoptive | 5 | 2020 | 13 | 1.850 |
Why?
|
| Kidney Neoplasms | 8 | 2021 | 65 | 1.820 |
Why?
|
| Immunity, Innate | 7 | 2019 | 135 | 1.690 |
Why?
|
| Cytotoxicity, Immunologic | 8 | 2019 | 22 | 1.560 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 5 | 2020 | 17 | 1.530 |
Why?
|
| Antibodies, Monoclonal | 3 | 2019 | 282 | 1.370 |
Why?
|
| Immunomodulation | 4 | 2019 | 13 | 1.350 |
Why?
|
| Adaptive Immunity | 5 | 2019 | 27 | 1.350 |
Why?
|
| Cytokines | 6 | 2021 | 569 | 1.280 |
Why?
|
| Antigens, Neoplasm | 5 | 2015 | 56 | 1.280 |
Why?
|
| Animals | 44 | 2023 | 14307 | 1.180 |
Why?
|
| Thymus Gland | 7 | 2004 | 77 | 1.120 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2022 | 184 | 1.110 |
Why?
|
| Lymphoma, T-Cell | 6 | 2003 | 25 | 1.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2019 | 19 | 0.940 |
Why?
|
| Mice, Inbred BALB C | 15 | 2021 | 649 | 0.870 |
Why?
|
| Mice | 26 | 2023 | 5668 | 0.850 |
Why?
|
| Signal Transduction | 16 | 2021 | 1802 | 0.820 |
Why?
|
| Receptors, Notch | 4 | 2020 | 32 | 0.800 |
Why?
|
| Proteasome Endopeptidase Complex | 3 | 2017 | 109 | 0.790 |
Why?
|
| Adenocarcinoma | 2 | 2017 | 239 | 0.780 |
Why?
|
| Neuroimmunomodulation | 1 | 2020 | 13 | 0.770 |
Why?
|
| Tumor Escape | 7 | 2020 | 12 | 0.760 |
Why?
|
| Neurotransmitter Agents | 1 | 2020 | 57 | 0.750 |
Why?
|
| Dendritic Cells | 2 | 2019 | 112 | 0.740 |
Why?
|
| Fas Ligand Protein | 4 | 2015 | 16 | 0.710 |
Why?
|
| Humans | 38 | 2023 | 34853 | 0.690 |
Why?
|
| NF-kappa B | 3 | 2017 | 306 | 0.670 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 178 | 0.640 |
Why?
|
| Natural Killer T-Cells | 1 | 2017 | 9 | 0.620 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2017 | 4 | 0.610 |
Why?
|
| Fibrosarcoma | 1 | 2017 | 7 | 0.610 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2021 | 781 | 0.610 |
Why?
|
| Combined Modality Therapy | 5 | 2019 | 142 | 0.600 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 32 | 0.590 |
Why?
|
| Cancer Vaccines | 2 | 2020 | 21 | 0.590 |
Why?
|
| Breast Neoplasms | 3 | 2017 | 1426 | 0.590 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2015 | 84 | 0.580 |
Why?
|
| Boronic Acids | 4 | 2010 | 19 | 0.580 |
Why?
|
| Pyrazines | 4 | 2010 | 23 | 0.570 |
Why?
|
| Cell Line, Tumor | 12 | 2023 | 2128 | 0.560 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2015 | 6 | 0.560 |
Why?
|
| MicroRNAs | 1 | 2021 | 386 | 0.550 |
Why?
|
| Immune System Diseases | 1 | 2015 | 20 | 0.550 |
Why?
|
| Mice, Transgenic | 5 | 2017 | 608 | 0.460 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 3 | 2010 | 10 | 0.440 |
Why?
|
| Aging | 3 | 2022 | 639 | 0.430 |
Why?
|
| Homeodomain Proteins | 2 | 2015 | 128 | 0.420 |
Why?
|
| Receptor Cross-Talk | 1 | 2011 | 16 | 0.420 |
Why?
|
| Apoptosis | 8 | 2021 | 1317 | 0.420 |
Why?
|
| Virus Diseases | 1 | 2011 | 21 | 0.420 |
Why?
|
| Neoplasm Transplantation | 7 | 2010 | 114 | 0.410 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 82 | 0.390 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 2 | 2010 | 2 | 0.390 |
Why?
|
| Cell Count | 2 | 2013 | 129 | 0.390 |
Why?
|
| Calcium | 5 | 2017 | 445 | 0.380 |
Why?
|
| Mastocytoma | 1 | 2010 | 4 | 0.370 |
Why?
|
| Lymphocyte Activation | 8 | 2016 | 222 | 0.370 |
Why?
|
| Antigen Presentation | 1 | 2009 | 54 | 0.350 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 2 | 2008 | 9 | 0.350 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2010 | 57 | 0.330 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2008 | 30 | 0.320 |
Why?
|
| Mast-Cell Sarcoma | 1 | 2007 | 1 | 0.320 |
Why?
|
| Gene Expression Regulation | 3 | 2019 | 968 | 0.310 |
Why?
|
| Mitochondria | 3 | 2016 | 454 | 0.310 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2021 | 35 | 0.300 |
Why?
|
| Disease Models, Animal | 4 | 2021 | 1300 | 0.290 |
Why?
|
| Ascites | 3 | 2000 | 4 | 0.290 |
Why?
|
| Cell Cycle Proteins | 2 | 2021 | 220 | 0.290 |
Why?
|
| Membrane Proteins | 5 | 2019 | 486 | 0.280 |
Why?
|
| Homeostasis | 4 | 2022 | 172 | 0.280 |
Why?
|
| Immunologic Surveillance | 2 | 2019 | 5 | 0.280 |
Why?
|
| Chemokines | 2 | 2016 | 89 | 0.270 |
Why?
|
| Female | 16 | 2021 | 19873 | 0.260 |
Why?
|
| Flavoproteins | 2 | 2000 | 15 | 0.230 |
Why?
|
| Thymus Extracts | 1 | 2003 | 5 | 0.230 |
Why?
|
| Flow Cytometry | 3 | 2015 | 392 | 0.230 |
Why?
|
| Inflammation | 3 | 2017 | 577 | 0.230 |
Why?
|
| Calcium-Binding Proteins | 3 | 2019 | 72 | 0.230 |
Why?
|
| Neoplasms, Experimental | 1 | 2003 | 36 | 0.230 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2015 | 89 | 0.220 |
Why?
|
| Immunoblotting | 2 | 2015 | 170 | 0.210 |
Why?
|
| Adjuvants, Immunologic | 1 | 2003 | 106 | 0.210 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2022 | 58 | 0.210 |
Why?
|
| Cell Survival | 3 | 2016 | 818 | 0.200 |
Why?
|
| Melanoma, Experimental | 1 | 2021 | 9 | 0.200 |
Why?
|
| Poly I-C | 1 | 2021 | 7 | 0.200 |
Why?
|
| Withanolides | 1 | 2021 | 8 | 0.200 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 46 | 0.200 |
Why?
|
| alpha-Defensins | 1 | 2021 | 15 | 0.200 |
Why?
|
| Enterotoxins | 1 | 2021 | 32 | 0.200 |
Why?
|
| Organoids | 1 | 2021 | 20 | 0.200 |
Why?
|
| Cell Differentiation | 3 | 2019 | 562 | 0.190 |
Why?
|
| Carcinoma, Large Cell | 1 | 2020 | 3 | 0.190 |
Why?
|
| Colitis, Ulcerative | 1 | 2021 | 49 | 0.190 |
Why?
|
| Crohn Disease | 1 | 2021 | 55 | 0.190 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2020 | 58 | 0.190 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2022 | 137 | 0.190 |
Why?
|
| Colon | 1 | 2021 | 98 | 0.190 |
Why?
|
| RNA Interference | 1 | 2021 | 225 | 0.180 |
Why?
|
| Calcium Signaling | 3 | 2017 | 95 | 0.180 |
Why?
|
| Biological Products | 1 | 2021 | 67 | 0.180 |
Why?
|
| Mice, Knockout | 3 | 2019 | 897 | 0.180 |
Why?
|
| Caspase 8 | 2 | 2010 | 31 | 0.180 |
Why?
|
| Models, Immunological | 1 | 2019 | 20 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2017 | 245 | 0.160 |
Why?
|
| Protease Inhibitors | 2 | 2008 | 47 | 0.160 |
Why?
|
| Leukemia | 2 | 2016 | 54 | 0.160 |
Why?
|
| Pore Forming Cytotoxic Proteins | 2 | 2015 | 4 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 984 | 0.160 |
Why?
|
| Antigens, CD1 | 1 | 2017 | 4 | 0.150 |
Why?
|
| Aging, Premature | 1 | 2017 | 4 | 0.150 |
Why?
|
| Mice, Inbred DBA | 2 | 2010 | 69 | 0.150 |
Why?
|
| Organ Specificity | 2 | 2010 | 123 | 0.150 |
Why?
|
| Male | 11 | 2021 | 18870 | 0.150 |
Why?
|
| Receptors, Cytokine | 1 | 2017 | 11 | 0.150 |
Why?
|
| Osteopontin | 1 | 2017 | 35 | 0.150 |
Why?
|
| Gene Expression Profiling | 2 | 2013 | 600 | 0.150 |
Why?
|
| Cell Proliferation | 3 | 2021 | 1149 | 0.150 |
Why?
|
| Trialkyltin Compounds | 1 | 2016 | 2 | 0.150 |
Why?
|
| Membrane Glycoproteins | 3 | 2020 | 197 | 0.150 |
Why?
|
| STAT5 Transcription Factor | 1 | 2017 | 44 | 0.150 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 859 | 0.140 |
Why?
|
| Butyrates | 1 | 2016 | 31 | 0.140 |
Why?
|
| Nystatin | 1 | 2016 | 6 | 0.140 |
Why?
|
| beta-Cyclodextrins | 1 | 2016 | 22 | 0.140 |
Why?
|
| Transcription Factors | 1 | 2021 | 653 | 0.140 |
Why?
|
| Clinical Trials as Topic | 2 | 2015 | 195 | 0.140 |
Why?
|
| Neuronal Ceroid-Lipofuscinoses | 1 | 2015 | 4 | 0.140 |
Why?
|
| T-Box Domain Proteins | 1 | 2015 | 7 | 0.140 |
Why?
|
| Granzymes | 1 | 2015 | 16 | 0.140 |
Why?
|
| Membrane Microdomains | 1 | 2016 | 46 | 0.140 |
Why?
|
| Energy Metabolism | 1 | 2017 | 160 | 0.140 |
Why?
|
| Genes, ras | 1 | 2015 | 22 | 0.140 |
Why?
|
| Bystander Effect | 1 | 2015 | 10 | 0.140 |
Why?
|
| Genetic Engineering | 1 | 2015 | 31 | 0.130 |
Why?
|
| Autoimmunity | 1 | 2015 | 52 | 0.130 |
Why?
|
| Inflammation Mediators | 1 | 2016 | 120 | 0.130 |
Why?
|
| Immunologic Factors | 1 | 2015 | 44 | 0.130 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2015 | 57 | 0.130 |
Why?
|
| Ubiquitin | 1 | 2015 | 76 | 0.130 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2015 | 79 | 0.130 |
Why?
|
| Air Pollutants | 1 | 2016 | 90 | 0.130 |
Why?
|
| Benzo(a)pyrene | 1 | 2016 | 122 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2015 | 200 | 0.130 |
Why?
|
| Adoptive Transfer | 2 | 2015 | 48 | 0.130 |
Why?
|
| Melanoma | 1 | 2015 | 91 | 0.130 |
Why?
|
| NFATC Transcription Factors | 1 | 2014 | 6 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2007 | 325 | 0.120 |
Why?
|
| Mutation | 2 | 2015 | 1023 | 0.120 |
Why?
|
| Environmental Pollutants | 1 | 2016 | 166 | 0.120 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2015 | 166 | 0.120 |
Why?
|
| Graft Rejection | 2 | 2019 | 38 | 0.120 |
Why?
|
| Mice, SCID | 2 | 2015 | 143 | 0.120 |
Why?
|
| Aged | 2 | 2022 | 6448 | 0.120 |
Why?
|
| Gene Expression | 1 | 2016 | 639 | 0.110 |
Why?
|
| Ligands | 2 | 2020 | 317 | 0.110 |
Why?
|
| Caspase 3 | 2 | 2016 | 194 | 0.110 |
Why?
|
| Cell Lineage | 2 | 2021 | 88 | 0.110 |
Why?
|
| Macrophages | 1 | 2016 | 431 | 0.110 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 251 | 0.110 |
Why?
|
| Receptor, Notch1 | 1 | 2011 | 16 | 0.100 |
Why?
|
| DNA Fragmentation | 2 | 2003 | 91 | 0.100 |
Why?
|
| Cells, Cultured | 4 | 2021 | 1442 | 0.100 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2016 | 146 | 0.100 |
Why?
|
| Survival Rate | 2 | 2020 | 310 | 0.100 |
Why?
|
| Apoptosis Inducing Factor | 2 | 2000 | 7 | 0.100 |
Why?
|
| Death Domain Receptor Signaling Adaptor Proteins | 1 | 2010 | 3 | 0.100 |
Why?
|
| Interferon-gamma | 2 | 2003 | 235 | 0.090 |
Why?
|
| Lymphocyte Cooperation | 1 | 2010 | 6 | 0.090 |
Why?
|
| Clonal Deletion | 1 | 2010 | 3 | 0.090 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2010 | 4 | 0.090 |
Why?
|
| Immunologic Memory | 1 | 2010 | 38 | 0.090 |
Why?
|
| Cell Growth Processes | 1 | 2010 | 41 | 0.090 |
Why?
|
| Autoantigens | 1 | 2010 | 82 | 0.090 |
Why?
|
| Immunity, Cellular | 1 | 2010 | 68 | 0.090 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2010 | 59 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2008 | 139 | 0.090 |
Why?
|
| Mitochondrial Membranes | 1 | 2008 | 38 | 0.080 |
Why?
|
| Mice, Mutant Strains | 1 | 2007 | 78 | 0.080 |
Why?
|
| Immune System | 1 | 2007 | 40 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 298 | 0.070 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2006 | 53 | 0.070 |
Why?
|
| Receptors, Immunologic | 1 | 2006 | 59 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 2 | 2015 | 1530 | 0.070 |
Why?
|
| Autoimmune Diseases | 1 | 2006 | 55 | 0.070 |
Why?
|
| Radiation Chimera | 1 | 2004 | 7 | 0.060 |
Why?
|
| Bone Marrow Transplantation | 1 | 2004 | 15 | 0.060 |
Why?
|
| Stromal Cells | 1 | 2004 | 45 | 0.060 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2004 | 43 | 0.060 |
Why?
|
| Receptor, Adenosine A2B | 1 | 2023 | 4 | 0.060 |
Why?
|
| Atrophy | 1 | 2004 | 40 | 0.060 |
Why?
|
| Reactive Oxygen Species | 2 | 2017 | 416 | 0.060 |
Why?
|
| Phosphates | 1 | 2023 | 49 | 0.060 |
Why?
|
| Adenosine | 1 | 2023 | 54 | 0.060 |
Why?
|
| Stress, Physiological | 1 | 2004 | 137 | 0.060 |
Why?
|
| Organ Size | 1 | 2003 | 148 | 0.060 |
Why?
|
| Interferon Inducers | 1 | 2021 | 2 | 0.050 |
Why?
|
| Mucin-6 | 1 | 2021 | 6 | 0.050 |
Why?
|
| Ascitic Fluid | 1 | 2000 | 7 | 0.050 |
Why?
|
| Organ Culture Techniques | 1 | 2021 | 99 | 0.050 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2000 | 21 | 0.050 |
Why?
|
| Nucleosomes | 1 | 2000 | 27 | 0.050 |
Why?
|
| Culture Media | 1 | 2000 | 84 | 0.050 |
Why?
|
| Carboplatin | 1 | 2020 | 13 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 217 | 0.050 |
Why?
|
| Thymosin | 1 | 2000 | 1 | 0.050 |
Why?
|
| Antibodies | 1 | 2000 | 135 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 242 | 0.050 |
Why?
|
| Oligopeptides | 1 | 2000 | 97 | 0.050 |
Why?
|
| Mice, Nude | 1 | 2021 | 323 | 0.050 |
Why?
|
| Biological Factors | 1 | 2000 | 6 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2020 | 48 | 0.050 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 2000 | 21 | 0.050 |
Why?
|
| Th2 Cells | 1 | 2000 | 56 | 0.050 |
Why?
|
| Endocytosis | 1 | 2020 | 104 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 480 | 0.050 |
Why?
|
| Th1 Cells | 1 | 2000 | 87 | 0.050 |
Why?
|
| Cell Division | 1 | 2000 | 296 | 0.050 |
Why?
|
| Cell Adhesion | 1 | 2020 | 209 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2021 | 107 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 195 | 0.040 |
Why?
|
| 3T3 Cells | 1 | 2019 | 58 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2000 | 140 | 0.040 |
Why?
|
| Heart Transplantation | 1 | 2019 | 43 | 0.040 |
Why?
|
| Proteomics | 1 | 2021 | 302 | 0.040 |
Why?
|
| Logistic Models | 1 | 2021 | 894 | 0.040 |
Why?
|
| Prognosis | 1 | 2020 | 707 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2021 | 366 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 964 | 0.040 |
Why?
|
| Sperm Count | 1 | 2017 | 25 | 0.040 |
Why?
|
| Sperm Motility | 1 | 2017 | 37 | 0.040 |
Why?
|
| U937 Cells | 1 | 2016 | 27 | 0.040 |
Why?
|
| HL-60 Cells | 1 | 2016 | 32 | 0.040 |
Why?
|
| Valproic Acid | 1 | 2016 | 14 | 0.040 |
Why?
|
| Sodium | 1 | 2016 | 101 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2016 | 135 | 0.040 |
Why?
|
| Chemokine CCL5 | 1 | 2016 | 38 | 0.040 |
Why?
|
| Lung | 1 | 2019 | 413 | 0.040 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 93 | 0.030 |
Why?
|
| Endoplasmic Reticulum | 1 | 2016 | 101 | 0.030 |
Why?
|
| Receptors, IgG | 1 | 2016 | 48 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 43 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2016 | 122 | 0.030 |
Why?
|
| Adiposity | 1 | 2017 | 145 | 0.030 |
Why?
|
| Glycolysis | 1 | 2015 | 66 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2021 | 1961 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 224 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 232 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2015 | 286 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2015 | 180 | 0.030 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2013 | 5 | 0.030 |
Why?
|
| Antigens, CD1d | 1 | 2013 | 5 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 834 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 114 | 0.030 |
Why?
|
| Recurrence | 1 | 2013 | 125 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 70 | 0.030 |
Why?
|
| Cell Movement | 1 | 2016 | 545 | 0.030 |
Why?
|
| Cell Line | 1 | 2016 | 1289 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 133 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 1124 | 0.020 |
Why?
|
| Protein Binding | 1 | 2014 | 913 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 1490 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 122 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 157 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 184 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2011 | 180 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2013 | 1349 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2010 | 423 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 209 | 0.020 |
Why?
|
| Perforin | 1 | 2008 | 9 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2008 | 117 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2010 | 490 | 0.020 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2006 | 1 | 0.020 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2006 | 21 | 0.020 |
Why?
|
| Middle Aged | 1 | 2020 | 9642 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 485 | 0.020 |
Why?
|
| Models, Biological | 1 | 2006 | 642 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2000 | 13 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 2000 | 44 | 0.010 |
Why?
|
| Gallic Acid | 1 | 2000 | 12 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2000 | 121 | 0.010 |
Why?
|